Navigation Links
Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
Date:5/14/2010

MORRISTOWN, N.J., May 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Fred Wilkinson, Watson's Executive Vice President, Global Brands, will provide an overview of the Company's business at the 2010 Citi Investment Research Global Healthcare Conference on Wednesday, May 26, 2010 at 4:30pm Eastern Daylight Time. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/citigroup/hc2010/94116472.cfm

An archived version will be available for 30 days after the live presentation and can be accessed at the same locations.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Reaches Settlement with Teva Over Seasonale(R)
2. Watson Confirms EVISTA(R) Patent Challenge
3. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
4. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
5. Watson Confirms Trilipix(R) Patent Challenge
6. Watson Confirms Rapamune(R) Patent Challenge
7. Watson Confirms Cenestin(R) Patent Challenge
8. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
9. Watson to Present at Barclays 2010 Global Healthcare Conference
10. Watson Receives FDA Approval for Generic Cardizem(R) LA
11. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):